Skip to content

Arrowhead Research ARWR Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$37.48M-93.5%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$4.29M+909%
Revvity logo
RevvityRVTY
-$74.69M-115%
Amgen logo
AmgenAMGN
-$959M-9.7%
Roivant Sciences logo
Roivant SciencesROIV
$63.23M
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
-$1.3M+94.4%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's change in accrued liabilities?
Arrowhead Research (ARWR) reported change in accrued liabilities of -$8.64M in Q1 2026.
How has Arrowhead Research's change in accrued liabilities changed year-over-year?
Arrowhead Research's change in accrued liabilities decreased by 132.4% year-over-year, from $26.61M to -$8.64M.
What does change in accrued liabilities mean?
The net change in expenses recognized but not yet paid in cash.
How do you interpret change in accrued liabilities?
An increase indicates rising unpaid obligations, while a decrease suggests the company is clearing its accrued expense backlog.
How does change in accrued liabilities compare across companies?
Common in R&D-heavy companies where clinical trial accruals fluctuate significantly.